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Numerous studies in the past 25 years have shown that 
most compounds, generated in metabolic processes 
(metabolic intermediates and products; endogenous 
compounds) or introduced orally or parenterally (nutritive 
compounds, medicaments, environmental toxins and other 
xenobiotics), do not enter or exit cells freely, by simple 
diffusion. Rather, their transmembrane movement is 
mediated by various membrane-bound proteins (transporters) 
localized in the cell membrane. Most membrane transporters 
belong to the SLC (SoLute Carriers) superfamily, which in 
humans encompass ~400 members grouped in 52 families 
(1). The functional properties and roles in cell physiology 
have been described for most of them, but about 40% of all 
SLCs are still orphans, without known substrates and 
biological characterization (1-5). The well-characterized 
members act as secondary- or tertiary-active exchangers, 
coupled transporters or electrochemically-driven facilitators 
in mediating the transport of amino acids, sugars, 
cholesterol, fatty acids, vitamins, inorganic ions, essential 
and some toxic metals, and various organic anions and 
cations, including drugs used in human and veterinary 
medicine. Depending on the electrochemical gradients of 
their substrates, these transporters can operate in influx or 
efflux mode, and are especially important in the intestine, 
liver and kidneys for handling the (re)absorptive and 
secretory processes. Due to their roles in the physiology of 
various organs, pathophysiology in various human diseases, 
and pharmacology (drug therapy, drug transport, drug-drug 
interactions, drug toxicity, drug development), the most 
characterized are the organic anion (OATs), cation (OCTs) 
and zwitterion transporters (family SLC22) (2-7), multidrug 
and toxins extruders (MATE/SLC47) (4, 8), and sodium-
independent (GLUTs/SLC2) and sodium-dependent 
(SGLTs/SLC5) glucose transporters (9-11). Functional 
defects or malfunctions of the specific SLC transporters 
due to either inactive gene, diminished gene expression, or 
single nucleotide polymorphisms (SNPs)-dependent gene 
variants have been implicated in various human conditions 
and diseases, such as primary carnithine deficiency, 
rheumatoid arthritis, inflammatory bowel disease, cisplatin-
induced toxicity, urolithiasis, mood-related disorders, 
diabetes, diminished renal secretion of organic anions and 
cations, variations in liver handling and renal secretion of 
organic cations, variations in drug pharmacokinetics and 
therapeutic efficiency, occurrence of drug-drug interactions 
and drug-induced organ toxicity, etc. (2, 4-6, 8). 
Another important superfamily of membrane 
transporters comprises several families of the primary-
active ABC (ATP Binding Cassette) members that operate 
as the ATP-driven efflux pumps (12). Most renown of these 
transporters are multidrug resistance protein 1/P-glycoprotein 
(MDR1/P-gp/ABCB1), various MRPs (multidrug resistance 
associated proteins/ABCC family), and breast cancer 
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resistance protein (BCRP/ABCG2). Their main 
physiological role is elimination from the cells and body 
various cationic and some anionic metabolic products which 
are too large to be substrates for the SLC transporters. In 
humans, P-gp is located in the intestinal and renal proximal 
tubule cells (apical membrane), hepatocytes (canalicular 
membrane), brain capillaries (endothelial cells, being an 
active component of blood brain barrier), and placental 
syncytiotrophoblast (apical membrane). As an efflux pump, 
P-gp exports various xenobiotics from these tissues, thus 
protecting them from drug toxicity but also causing 
resistance to various therapeutic drugs. MRPs are more 
ubiquitous, and also mediate multiple drug resistance to 
cancer therapy, whereas BCRP is particularly responsible 
for poor effects of breast cancer chemotherapy. In addition, 
variable effects of drug therapy, drug-drug interactions and 
drug-induced organ toxicity in different individuals, as well 
as some specific genetic diseases may be related to the gene 
polymorphism of these transporters (12-15). Recent studies 
have indicated that some transporters of the ABC families 
(and also from the SLC families) can be therapeutic or 
diagnostic targets in specific diseases. 
In vitro studies on identification and detailed molecular 
characterization of various membrane transporters, 
followed or complemented by the in vivo evaluation of its 
physiological and/or defence role in established animal 
research models, represents an important and well-
established research area in pharmacology and toxicology. 
However, although the orthologs of the above-mentioned 
human membrane transporters have been detected and 
extensively studied in rodents and other experimental 
animals, in many aspects their translational relevance to 
human transporters appear to be questionable due to species 
differences in their characteristics and expression (16).
From the viewpoint of environmental toxicology, 
however, membrane transporters are important as integral 
elements of the cellular defence mechanisms involved in 
processing of endo- and xenobiotics in other animals. For 
example, aquatic organisms are continuously exposed to a 
variety of environmental chemicals originating from various 
anthropogenic sources, and evolutionary conserved cellular 
defence mechanisms that mediate the overall bioavailability 
and potential toxicity of xenobiotics have been shown to 
be similar to those described in mammals. They include the 
regulation of absorption by uptake (SLC) transporters, the 
well-documented biotransformation by phase I and phase 
II enzymes (17), and finally the more recently demonstrated 
active efflux of xenobiotics by the ABC proteins (18). 
Furthermore, recent ecotoxicological studies have shown 
that the expression levels of some membrane transporters 
in specific organs of wild animals may be relevant indicators 
of the environmental pollution (17, 19). Finally, it has been 
demonstrated that the transport activity of ABC transporters 
can be sensitive to the presence of environmental chemicals 
which can act as specific inhibitors (18, 20, 21). These 
chemicals have the potential to block the ABC transporters’ 
mediated active efflux of xenobiotics, causing a significant 
increase in their intracellular accumulation. From an 
ecotoxicological viewpoint, the main consequence of this 
type of inhibition is an increase in sensitivity of aquatic 
organisms toward the many xenobiotics typically present 
in aquatic environments. 
Studies on the role of membrane transporters in 
ecotoxicological context are rare in comparison to efforts 
in mainstream toxicology, especially regarding research on 
SLC transporters. Despite their physiological importance 
and well documented role in the cellular detoxification in 
mammals, none of these transporters have been characterized 
in non-mammalian organisms before recent studies done 
on zebrafish (22-24), and the knowledge about polyspecific 
uptake transporters in non-mammalian species remains 
modest. Consequently, apart from new insights relevant for 
our fundamental understanding of the evolution, biological 
role and (eco)toxicological significance of polyspecific 
membrane transporters, this type of research is a necessary 
prerequisite for a better understanding and ultimately 
prediction of toxicity, and should enable a more reliable 
risk assessment in the context of both human and 
environmental toxicology.
All these findings in the fast-growing field of membrane 
transporters led us to organize the 1st Croatian symposium 
on membrane transporters in 2013, which largely dealt with 
the physiological aspects of transporters in various 
experimental models performed by Croatian scientists in 
the Croatian research institutions. The presentations were 
held in Croatian. The present symposium was designed to 
be more international, with contributions from a few renown 
scientists from abroad, with all presentations in English and 
focused on a few selected transporters with a view toward 
the increasingly important pharmacological and (eco)
toxicological impacts.
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